InsiderTrades

Form 4 for RVMD Revolution Medicines, Inc.

Accepted 2022-03-04 00:00:00 ET · period of report 2020-02-18 · accession 0001209191-22-016484 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DMI 2022-03-04 2020-02-18+ RVMD Schroeder Thilo Dir P - Purchase $26.30 +1.09M 2.67M +69% +$28.62M
DI 2022-03-04 2020-02-18 RVMD Schroeder Thilo Dir C - Cnv Deriv — +2.12M 2.12M New —
DMI 2022-03-04 2020-02-18 RVMD Schroeder Thilo Dir C - Cnv Deriv — -2.12M 0 -100% —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-03-04 P A 56,300 $17.69 238,227 I By Nextech Crossover I SCSP — — (F8) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.25 to $18.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. (F5) Nextech Invest AG is the investment advisor of Nextech Crossover I SCSP ("Nextech Crossover"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech Crossover. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
2 Common Common Stock 2021-02-08 P A 300,000 $45.00 300,000 I By Nextech VI Oncology SCSp — — (F3) Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
3 Common Common Stock 2022-03-02 P A 116,290 $18.94 116,290 I By Nextech Crossover I SCSP — — (F4) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.62 to $19.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. (F5) Nextech Invest AG is the investment advisor of Nextech Crossover I SCSP ("Nextech Crossover"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech Crossover. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
4 Common Common Stock 2022-03-03 P A 54,764 $18.42 171,054 I By Nextech Crossover I SCSP — — (F6) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.03 to $18.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. (F5) Nextech Invest AG is the investment advisor of Nextech Crossover I SCSP ("Nextech Crossover"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech Crossover. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
5 Common Common Stock 2022-03-03 P A 10,873 $19.13 181,927 I By Nextech Crossover I SCSP — — (F7) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.05 to $19.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. (F5) Nextech Invest AG is the investment advisor of Nextech Crossover I SCSP ("Nextech Crossover"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech Crossover. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
6 Common Common Stock 2020-02-18 P A 400,000 $17.00 2,518,214 I By Nextech V Oncology S.C.S., SICAV-SIF — — (F2) Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF ("Nextech V"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech V. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
7 Common Common Stock 2020-02-18 C A 2,118,214 — 2,118,214 I By Nextech V Oncology S.C.S., SICAV-SIF — — (F1) Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. (F2) Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF ("Nextech V"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech V. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
8 Common Common Stock 2020-07-13 P A 150,000 $26.00 2,668,214 I By Nextech V Oncology S.C.S., SICAV-SIF — — (F2) Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF ("Nextech V"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech V. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
9 Derivative Series B Preferred Stock 2020-02-18 C D 1,569,539 — 0 I By Nextech V Oncology S.C.S., SICAV-SIF — · — to — 1,569,539 Common Stock (F1) Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. (F2) Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF ("Nextech V"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech V. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
10 Derivative Series C Preferred Stock 2020-02-18 C D 548,675 — 0 I By Nextech V Oncology S.C.S., SICAV-SIF — · — to — 548,675 Common Stock (F1) Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. (F2) Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF ("Nextech V"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech V. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.